Ades L, Guerci-Bresler A, Cony-Makhoul P, Legros L, Sebert M, Braun T, Delaunay J, Desseaux K, Chevret S, Fenaux P; GROUPE FRANCOPHONE DES MYELODYSPLASIES (GFM).
A phase II study of the efficacy and safety of an intensified schedule of azacitidine in intermediate-2 and high risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des myelodysplasies (GFM).
Haematologica. 2018 Oct 31. pii: haematol.2018.203885. doi: 10.3324/haematol.2018.203885.
https://www.ncbi.nlm.nih.gov/pubmed/30381302